Munson Medical Center
- Type
- Teaching hospital
- Where
- Traverse City, MI
- Medicare CCN
- 230097
- Received
- $230,101 in 102 records, 2020 ($10,644 general, $219,456 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: MUNSON MEDICAL CENTER,CORPORATION Fuzzy (name and state)
- Nonprofit contractor: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: MUNSON MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 30 | $10,644 |
| 2020 | Research payment | 72 | $219,456 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Medical Device Business Services, Inc. | 9 | $60,687 | 2020 |
| Merck Sharp & Dohme LLC | 8 | $53,346 | 2020 |
| Abbott Laboratories | 30 | $41,903 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $39,534 | 2020 |
| Amgen Inc. | 2 | $11,004 | 2020 |
| BIOTRONIK INC. | 16 | $8,461 | 2020 |
| Tandem Diabetes Care, Inc. | 23 | $6,200 | 2020 |
| Medtronic MiniMed, Inc. | 4 | $3,975 | 2020 |
| Boston Scientific Corporation | 5 | $2,849 | 2020 |
| SANOFI US SERVICES INC. | 2 | $2,030 | 2020 |
| Siemens Medical Solutions USA, Inc. | 1 | $82 | 2020 |
| Linvatec Corporation | 1 | $27 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 72 | $219,456 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 28 | $10,535 |
| Charitable Contribution | 1 | $82 |
| Grant | 1 | $27 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $82 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-29 | Amgen Inc. | $11,000 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-12-22 | Medtronic MiniMed, Inc. | $1,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-12-17 | Bayer Healthcare Pharmaceuticals Inc. | $39,534 | Research payment | Cash or cash equivalent | Xofigo Drug, Oncology | Bay88-8223 Alpharadin Combo with abiraterone in CRPC | 2020 |
| 2020-12-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $826 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-11-10 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-11-05 | Abbott Laboratories | $50 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $197 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $143 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $143 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $48 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $16 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-02 | Medical Device Business Services, Inc. | $800 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-10-28 | Abbott Laboratories | $6,006 | Research payment | Cash or cash equivalent | Nanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2020 |
| 2020-10-28 | Abbott Laboratories | $375 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-28 | Abbott Laboratories | $35 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-10-21 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-21 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Abbott Laboratories | $1,180 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-05 | Medical Device Business Services, Inc. | $500 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-10-01 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-01 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-01 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-01 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-23 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-17 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Nanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2020 |
| 2020-09-08 | Medtronic MiniMed, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-08-26 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-08-26 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-08-20 | Abbott Laboratories | $450 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2020 |
| 2020-08-13 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Nanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2020 |
| 2020-08-13 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-08-12 | Abbott Laboratories | $2,245 | Research payment | Cash or cash equivalent | Nanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2020 |
| 2020-07-29 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-07-22 | Abbott Laboratories | $1,125 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-07-06 | Boston Scientific Corporation | $141 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-06-17 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-06-16 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-06-16 | Abbott Laboratories | $375 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-06-09 | Medtronic MiniMed, Inc. | $425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-05-28 | Abbott Laboratories | $360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-05-26 | Merck Sharp & Dohme LLC | $55 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2020 |
| 2020-05-14 | SANOFI US SERVICES INC. | $1,450 | Research payment | Cash or cash equivalent | ALPROLIX Biological, Hematology | Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B | 2020 |
| 2020-05-14 | SANOFI US SERVICES INC. | $580 | Research payment | Cash or cash equivalent | ALPROLIX Biological, Hematology | Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B | 2020 |
| 2020-05-11 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2020 |
| 2020-05-04 | Medical Device Business Services, Inc. | $800 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-04-30 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-04-29 | Abbott Laboratories | $793 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-04-24 | Abbott Laboratories | $200 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-04-22 | Abbott Laboratories | $2,641 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-04-20 | Merck Sharp & Dohme LLC | $174 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-04-17 | Merck Sharp & Dohme LLC | $415 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2020 |
| 2020-04-15 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-04-09 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-04-06 | Boston Scientific Corporation | $156 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-03-19 | Linvatec Corporation | $27 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-03-17 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-03-16 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | GENERAL - TACHY Device, TACHY | LSS OF 4 SITE | 2020 |
| 2020-03-16 | Boston Scientific Corporation | $725 | Research payment | Cash or cash equivalent | GENERAL - TACHY Device, TACHY | LSS OF 4 SITE | 2020 |
| 2020-03-10 | Merck Sharp & Dohme LLC | $151 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2020 |
| 2020-03-10 | Merck Sharp & Dohme LLC | $93 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-03-05 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-03-02 | Medical Device Business Services, Inc. | $1,000 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-02-27 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-02-19 | BIOTRONIK INC. | $5,000 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-02-19 | BIOTRONIK INC. | $2,500 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-02-19 | Merck Sharp & Dohme LLC | $345 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-02-12 | Abbott Laboratories | $1,703 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-02-03 | Medical Device Business Services, Inc. | $400 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-01-30 | Abbott Laboratories | $100 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-01-29 | Abbott Laboratories | $3,518 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-01-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-01-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-01-28 | Medtronic MiniMed, Inc. | $775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-01-22 | Abbott Laboratories | $3,850 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-01-22 | Abbott Laboratories | $2,595 | Research payment | Cash or cash equivalent | Nanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2020 |
| 2020-01-17 | Abbott Laboratories | $6,000 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | Abbott Vascular / XIENCE | 2020 |
| 2020-01-16 | Abbott Laboratories | $50 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-01-14 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-01-09 | Amgen Inc. | $4 | Research payment | In-kind items and services | GALACTIC - HF | 2020 | |
| 2020-01-08 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-01-06 | Medical Device Business Services, Inc. | $45,447 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-01-06 | Medical Device Business Services, Inc. | $6,900 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-01-06 | Medical Device Business Services, Inc. | $4,200 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 | |
| 2020-01-06 | Medical Device Business Services, Inc. | $640 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Traverse City, MI, county Grand Traverse County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Traverse City, MI | County Grand Traverse County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 15,593 | 96,166 | 10,077,761 |
| Population, 2020 census P1 | 15,678 | 95,238 | 10,077,331 |
| Median age B01002 | 42.7 | 43.5 | 40.2 |
| Under 18 B01001 | 16.6% | 19.4% | 21.2% |
| 65 and over B01001 | 23.9% | 22.0% | 18.6% |
| Households B11001 | 7,191 | 40,287 | 4,076,369 |
| Foreign born B05002 | 2.5% | 2.0% | 7.2% |
| Median household income B19013 | $74,087 | $81,647 | $72,875 |
| Median family income B19113 | $106,362 | $101,748 | $93,357 |
| Per capita income B19301 | $53,432 | $45,034 | $40,735 |
| Poverty rate B17001 | 12.3% | 9.6% | 13.2% |
| Unemployment rate B23025 | 5.2% | 3.8% | 5.7% |
| Civilian labor force B23025 | 8,267 | 50,787 | 5,018,449 |
| Mean commute (minutes) B08013 | 17.2 | 20.6 | 24.2 |
| Bachelor's degree or higher B15003 | 47.4% | 40.6% | 32.4% |
| Housing units B25001 | 8,479 | 47,003 | 4,622,236 |
| Owner-occupied B25003 | 63.7% | 77.2% | 73.2% |
| Renters B25003 | 36.3% | 22.8% | 26.8% |
| Median home value B25077 | $415,400 | $339,400 | $231,600 |
| Median gross rent B25064 | $995 | $1,288 | $1,129 |
| White, not Hispanic B03002 | 87.7% | 90.5% | 72.4% |
| Black B03002 | 1.3% | 0.8% | 13.1% |
| Hispanic or Latino B03002 | 3.6% | 3.4% | 5.9% |
| Asian B03002 | 1.1% | 0.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.4% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Traverse City, MI.
Comments